CN1171242A - Compound anticancer Chinese medicine - Google Patents
Compound anticancer Chinese medicine Download PDFInfo
- Publication number
- CN1171242A CN1171242A CN 96110537 CN96110537A CN1171242A CN 1171242 A CN1171242 A CN 1171242A CN 96110537 CN96110537 CN 96110537 CN 96110537 A CN96110537 A CN 96110537A CN 1171242 A CN1171242 A CN 1171242A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- tumor
- restrain
- compound anti
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An anticancer compound Chinese medicine in the form of powder, pill, tablet, or oral liquid for treating liver cancer,stomach cancer and lung cancer with high curative effect and no toxic by -effect is prepared from 10 Chinese medicinal materials such as ginseng dried in sun (5 -20 wt. portions), prepared pinellia tuber (6 -15), bupleurum root (8 -20), Chinese angilica root (9 -15), oldenlandia (20 -75), etc.
Description
The invention belongs to a kind of medicinal preparation, particularly a kind of compound anti-cancer Chinese medicine.
Traditional cancer therapy is operation, radiation and chemotherapy three big means, and preceding two kinds of methods have developed into peak and platform area at present, can't improve the cure rate of infiltration and metastatic cancer again; Chemotherapy is big to the body toxic and side effects, makes the part patient be difficult for accepting.And the research and development of new anticancer Western medicine takes length, expensive big, and easily produces drug resistance, also is difficult to improve curative effect again.It is that precentagewise is carried out that moreover Western medicine kills and wounds cancerous cell, and promptly the thorough never kill cancer cell of simple western medicine has only at last by body's immunity and removes Western medicine not dead that part of cancerous cell extremely, thoroughly healing cancer patient.At present all Western medicine anticarcinogen all have and lower immunity function in various degree, promptly chemotherapy with medicine the more, immunologic function is lower, after chemotherapy stopped, not killed cancerous cell was in the low situation of body's immunity, very fast breeding, tumor further develops.And the existing most clinical efficacy of Chinese medicine anticarcinogen is not too obvious, and some toxic and side effects is bigger, rather treats the esophageal carcinoma as esophagus, perforation of esophagus occurs behind part patient's clothes, or causes digestive tract hemorrhage.The scope of application that has is little, as eliminating mass the liver benefiting sheet hepatocarcinoma is had certain effect, but clinical practice only limits to hepatocarcinoma.
The object of the present invention is to provide a kind of curative effect height, the compound anti-cancer Chinese medicine that has no side effect.
For reaching above-mentioned purpose, the present invention adopts following technical scheme: compound anti-cancer Chinese medicine " tumor must restrain ", contain parts by weight 5-20 part Radix Ginseng, 6-15 part Rhizoma Pinelliae Preparata, 8-20 part Radix Bupleuri, 9-15 part Radix Angelicae Sinensis, 20-75 part Herba Hedyotidis Diffusae, 20-75 part Herba Solani Nigri, 20-75 part Herba Scutellariae Barbatae.
Described compound anti-cancer Chinese medicine " tumor must restrain " also contains parts by weight 10-20 part Rhizoma Curcumae, 10-15 part Nidus Vespae, 20-40 part Fructus Trichosanthis.
Described compound anti-cancer Chinese medicine " tumor must restrain ", all medicines are worn into fine powder, make through uniform mixing, packaging sterilizing.
Described compound anti-cancer Chinese medicine " tumor must restrain ", all medicines are worn into fine powder, and mixing water is general to be ball or tablet forming, and drying, packing, sterilization are made.
Described compound anti-cancer Chinese medicine " tumor must restrain ", Radix Ginseng is made fine powder, makes ball or sheet with the water drug-decocting concentrating liquid mix homogeneously of other medicines, and drying, packing, sterilization form.
Described compound anti-cancer Chinese medicine " tumor must restrain ", Radix Ginseng, Rhizoma Curcumae are made ball or sheet with the water drug-decocting concentrating liquid mix homogeneously of other medicines after making fine powder, and drying, packing, sterilization form.
Described compound anti-cancer Chinese medicine " tumor must restrain ", decocting liquid concentrates and makes oral liquid behind all medicine decoctings.
This medicine does not have contraindication, can take in case make a definite diagnosis.Using method, oral, every day 2-3 time, each 6-12 gram.
Below by 100 example life cycles of compound anti-cancer Chinese medicine " tumor must restrain " treatment advanced liver cancer and experimentation, clinical practice this medication effect and toxic and side effects size are explained.1, case is selected: all case all meets the clinical diagnosis standard that in December, 1977 whole nation hepatocarcinoma control cooperation meeting is drafted.Age limit is below 70 years old, and Ka Shi scores＞60, and darling renal function is normal substantially, does Abdominal B type ultrasonography, darling renal function and AFP quantitative check before and after the treatment." tumor must restrain " treatment group (observation group) 100 examples, male 75 examples, women 25 examples, age 34-70 year, 52.1 years old mean age, men and women's ratio 3: 1.Clinical typing: simple type 21 examples, atherosclerotic type 79 examples, AFP＞400ng/ml person's 72 examples.Clinical stages: II phases 30 example, III phases 70 example, pulmonary shifts 8 examples, and 4 examples are shifted in the abdominal cavity.Chemotherapy group (matched group) 26 examples, male 23 examples, women 3 examples, age 36-68 year, 51.5 years old mean age.Clinical typing: simple type 4 examples, atherosclerotic type 22 examples, AFP＞400ng/ml person's 22 examples.Clinical stages: II phases 7 example, III phases 19 example, two groups of comparabilities are strong.2, medication: observation group is with " tumor must restrain " treatment, every day three times, and each 8-10 gram, 60 days is a course of treatment, has a rest for 2 all second courses of treatment, the medication of this group is all at one more than the course of treatment.Matched group, chemotherapy regimen are AF:ADM30mg/m
2, d1, d21 administration, intravenous injection; 5-Fu300mg/m
2, quiet d1-5, d21-25, above medication is a course of treatment, have a rest and gave for second course of treatment in 30 days, this group medication person's course of treatment 26 examples, two the course of treatment person's 17 examples.3, result 1. life cycle: observation group's median survival interval 9 months, survival rate 34% in 1 year; Matched group median survival interval 3.5 months, survival rate 13% in 1 year.Lose and visit 5 examples, by last mistake visit time death, follow-up rate is 95%.Two groups of contrasts, median survival interval and the annual rate of depositing have highly significant difference, and prompting is to advanced liver cancer, and Chinese medicine " tumor must restrain " treatment is better than Western medicine.2. toxic and side effects: hemogram, darling renal function and digestive tract have no adverse reaction before and after the treatment of treatment group; Matched group is pressed the grouping of WHO chemotherapy toxic side effect grade scale, organizes above digestive tract reaction person 8 examples of II level entirely, accounts for 30%, and III level 3 examples account for 11%.Bone marrow toxicity, leukocyte are reduced to above person's 8 examples of II level, account for 30%, and platelet is reduced to above person's 4 examples of II level, accounts for 1 5%, blood urea nitrogen 1 example that raises, transaminase's 2 examples that raise.The prompting Chinese medicine " tumor must restrain " body is had no side effect, the result is consistent with its toxicity test, and Western medicine (ADM, 5-Fu) chemotherapy has certain toxicity to bone marrow, digestive tract, Liver and kidney.4, experimentation: using gastric syncarcinogen NSEE, to bring out the mice model of forestomach cancer be model, studied " tumor must restrain " brings out gastric cancer to NSEE inhibitory action.Test it in three batches.Dosage (4g/kgd in " tumor must restrain "
-17od) group carcinogenesis rate is 12.5%, 11.1% and 10.5%, and this model group reduces by 43.1%, 38.9%, 39.5% respectively, and cancer suppressing ratio is respectively 77.5%, 77.8%, 79%, with positive control, and medicine Bleomycin A5 (2 * 10
-3G/kgd
-110d) organize and compare no significant difference." tumor must restrain " three dosage groups (high, medium and low) have obvious inhibitory action to the mice model of forestomach cancer (squamous cell carcinoma) that NSEE brings out, and are especially good with middle dose effect, average cancer suppressing ratio 78.1%, and the animal toxicology experiment confirm has no side effect.
According to case statistics to 110 routine various cancer patients (containing hepatocarcinoma, gastric cancer, esophageal carcinoma, pulmonary carcinoma, breast carcinoma, laryngeal carcinoma), medicine of the present invention is 13.63% to the remission rate of cancer, effective percentage 46.35% (general treatment by Chinese herbs cancer effective percentage is lower than 5.2%), coefficient of stabilization 91.1%.
In addition, medicine of the present invention can be made into several dosage forms such as powder, pill or tablet and oral liquid etc., and powder processing is simple, and tablet, pill portably use all very convenient, and oral liquid then more helps taking and absorbing.
Embodiment 1, get 5 parts of (parts by weight of Radix Ginseng, down together), 6 parts of Rhizoma Pinelliae Preparata, 8 parts of Radix Bupleuri, 9 parts of Radix Angelicae Sinensis, 20 parts of Herba Hedyotidis Diffusaes, 20 parts of Herba Solani Nigris, 20 parts of Herba Scutellariae Barbataes, 10 parts of Rhizoma Curcumae, 10 parts of Nidus Vespaes, 20 parts of Fructus Trichosanthis are worn into fine powder, uniform mixing, the equivalent packing, sterilization treatment gets compound anti-cancer Chinese medicine " tumor must restrain " powder.
Embodiment 2, get 20 parts of Radix Ginseng, 15 parts of Rhizoma Pinelliae Preparata, 20 parts of Radix Bupleuri, 15 parts of Radix Angelicae Sinensis, 75 parts of Herba Solani Nigris, 75 parts of Herba Scutellariae Barbataes, 75 parts of Herba Hedyotidis Diffusaes, 20 parts of Rhizoma Curcumae, 15 parts of Nidus Vespaes, 40 parts of Fructus Trichosanthis, wear into fine powder, uniform mixing, water is general to be ball, and compound anti-cancer Chinese medicine " tumor must restrain " ball is made in drying, packing, sterilization.If compacting in flakes, compound anti-cancer Chinese medicine " tumor must restrain " sheet is made in drying, packing, sterilization.
Embodiment 3, get 7 parts of Radix Ginseng, 8 parts of Rhizoma Pinelliae Preparata, 10 parts of Radix Bupleuri, 12 parts of Radix Angelicae Sinensis, 30 parts of Herba Hedyotidis Diffusaes, 25 parts of Herba Solani Nigris, 28 parts of Herba Scutellariae Barbataes, 12 parts of Rhizoma Curcumae, 11 parts of Nidus Vespaes, 25 parts of Fructus Trichosanthis, concentrate behind all medicine decoctings, concentrated solution adds proper amount of sugar and antiseptic mixing, packing, compound anti-cancer Chinese medicine " tumor must restrain " oral liquid.
Embodiment 4, get 9 parts of Radix Ginseng, 10 parts of Rhizoma Pinelliae Preparata, 12 parts of Radix Bupleuri, 10 parts of Radix Angelicae Sinensis, 40 parts of Herba Solani Nigris, 45 parts of Herba Hedyotidis Diffusaes, 50 parts of Herba Scutellariae Barbataes.Radix Ginseng is worn into fine powder, makes ball or sheet with the water drug-decocting concentrating liquid mixing of other medicines, and drying, packing, sterilization get compound anti-cancer Chinese medicine " tumor must restrain " concentrated pill or sheet.
Embodiment 5, get 15 parts of Radix Ginseng, 12 parts of Rhizoma Pinelliae Preparata, 17 parts of Radix Bupleuri, 18 parts of Radix Angelicae Sinensis, 35 parts of Herba Solani Nigris, 50 parts of Herba Hedyotidis Diffusaes, 55 parts of Herba Scutellariae Barbataes, 17 parts of Rhizoma Curcumae, 13 parts of Nidus Vespaes, 35 parts of Fructus Trichosanthis.Radix Ginseng, Rhizoma Curcumae wear into fine powder together with the water drug-decocting concentrating liquid mixing of other medicines, make ball or sheet, drying, packing, sterilization, compound anti-cancer Chinese medicine " tumor must restrain " concentrated pill or sheet.
Claims (7)
1, compound anti-cancer Chinese medicine " tumor must restrain ", the present invention is characterised in that, contains parts by weight 5-20 part Radix Ginseng, 6-15 part Rhizoma Pinelliae Preparata, 8-20 part Radix Bupleuri, 9-15 part Radix Angelicae Sinensis, 20-75 part Herba Hedyotidis Diffusae, 20-75 part Herba Solani Nigri, 20-75 part Herba Scutellariae Barbatae.
2, compound anti-cancer Chinese medicine as claimed in claim 1 " tumor must restrain " is characterized in that, also contains parts by weight 10-20 part Rhizoma Curcumae, 10-15 part Nidus Vespae, 20-40 part Fructus Trichosanthis.
3, compound anti-cancer Chinese medicine as claimed in claim 1 or 2 " tumor must restrain " is characterized in that all medicines are worn into fine powder, makes through uniform mixing, packaging sterilizing.
4, compound anti-cancer Chinese medicine as claimed in claim 1 or 2 " tumor must restrain " is characterized in that all medicines are worn into fine powder, and mixing water is general to be ball or tablet forming, and drying, packing, sterilization are made.
5, compound anti-cancer Chinese medicine as claimed in claim 1 " tumor must restrain " is characterized in that Radix Ginseng is made fine powder, makes ball or sheet with the water drug-decocting concentrating liquid mix homogeneously of other medicines, and drying, packing, sterilization form.
6, compound anti-cancer Chinese medicine as claimed in claim 2 " tumor must restrain " is characterized in that, Radix Ginseng, Rhizoma Curcumae are made ball or sheet with the water drug-decocting concentrating liquid mix homogeneously of other medicines after making fine powder, and drying, packing, sterilization form.
7, compound anti-cancer Chinese medicine as claimed in claim 1 or 2 " tumor must restrain " is characterized in that, decocting liquid concentrates and makes oral liquid behind all medicine decoctings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96110537A CN1057220C (en) | 1996-07-19 | 1996-07-19 | Compound anticancer Chinese medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96110537A CN1057220C (en) | 1996-07-19 | 1996-07-19 | Compound anticancer Chinese medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1171242A true CN1171242A (en) | 1998-01-28 |
| CN1057220C CN1057220C (en) | 2000-10-11 |
Family
ID=5120848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96110537A Expired - Fee Related CN1057220C (en) | 1996-07-19 | 1996-07-19 | Compound anticancer Chinese medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1057220C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316119A (en) * | 2013-05-17 | 2013-09-25 | 胡庆华 | Traditional Chinese medicine for treating leukemia |
| CN103784552A (en) * | 2014-02-18 | 2014-05-14 | 朱良春 | Lung-tonifying and tumor-eliminating powder and preparation method and application thereof |
| CN104547866A (en) * | 2015-01-03 | 2015-04-29 | 覃昌明 | Traditional Chinese medicine preparation for treating stomach cancer |
| CN104623301A (en) * | 2015-03-16 | 2015-05-20 | 徐若曾 | Preparation for treating early-stage breast cancer and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020405C (en) * | 1988-08-22 | 1993-05-05 | 李兴尧 | Preparing method of ailingsan for curing and remitting cancer |
| CN1044561C (en) * | 1991-10-05 | 1999-08-11 | 邱兴军 | Combined medicine for treatment of carcinomatosis and manufacturing method thereof |
-
1996
- 1996-07-19 CN CN96110537A patent/CN1057220C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316119A (en) * | 2013-05-17 | 2013-09-25 | 胡庆华 | Traditional Chinese medicine for treating leukemia |
| CN103316119B (en) * | 2013-05-17 | 2014-08-06 | 胡庆华 | Traditional Chinese medicine for treating leukemia |
| CN103784552A (en) * | 2014-02-18 | 2014-05-14 | 朱良春 | Lung-tonifying and tumor-eliminating powder and preparation method and application thereof |
| CN103784552B (en) * | 2014-02-18 | 2015-09-09 | 朱良春 | Lung benefiting lumor eliminating powder and its production and use |
| CN104547866A (en) * | 2015-01-03 | 2015-04-29 | 覃昌明 | Traditional Chinese medicine preparation for treating stomach cancer |
| CN104623301A (en) * | 2015-03-16 | 2015-05-20 | 徐若曾 | Preparation for treating early-stage breast cancer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1057220C (en) | 2000-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537508A (en) | Antitumor drug | |
| CN101869667B (en) | Chinese herbal medicinal composition for treating lung cancer | |
| CN102743584A (en) | Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN1057220C (en) | Compound anticancer Chinese medicine | |
| CN1895337B (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving life quality of late tumor patient | |
| CN1507884A (en) | Chinese medicine powder and decoction composition for treating cancers | |
| CN103251741A (en) | Chinese medicine composition for treating toxoplasmosisinswine, and preparation method and application thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN102614283B (en) | Medicament for promoting postoperative gastrointestinal function recovery and application of medicament | |
| CN101804175A (en) | Anti-cancer Chinese medicinal powder and preparation method thereof | |
| CN1177598C (en) | Medicine for eliminating side effect of radiotherapy and chemotherapy to treat malignant tumor and its prepn | |
| CN102614365B (en) | Traditional Chinese medical composition for treatment of breast tumor | |
| CN102205109B (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN1079252C (en) | Compound graceful jassamine preparation | |
| CN1053362C (en) | Baicaoshengshou oral liquor and its preparation | |
| CN1074292C (en) | Cancer treating medicine capsule | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN107519261A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN100435824C (en) | Detoxifying formulation containing astragalus root and greenbrier and preparation process thereof | |
| CN1337251A (en) | Anticancer capsule | |
| CN104645173A (en) | Drug for treatment or adjuvant treatment of AIDS (Acquired Immune Deficiency Syndrome), and preparation method and use method thereof | |
| CN1080563C (en) | Series medicinal preparation for treating cancer and production method thereof | |
| CN101129997A (en) | Oral liquid of curcuma aromatica for relieving exterior syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |